| Literature DB >> 29686425 |
Mikhail Binnewies1, Edward W Roberts1, Kelly Kersten1, Vincent Chan2, Douglas F Fearon3, Miriam Merad4, Lisa M Coussens5, Dmitry I Gabrilovich6, Suzanne Ostrand-Rosenberg7,8, Catherine C Hedrick9, Robert H Vonderheide10, Mikael J Pittet11, Rakesh K Jain12, Weiping Zou13, T Kevin Howcroft14, Elisa C Woodhouse14, Robert A Weinberg15, Matthew F Krummel16,17.
Abstract
The clinical successes in immunotherapy have been both astounding and at the same time unsatisfactory. Countless patients with varied tumor types have seen pronounced clinical response with immunotherapeutic intervention; however, many more patients have experienced minimal or no clinical benefit when provided the same treatment. As technology has advanced, so has the understanding of the complexity and diversity of the immune context of the tumor microenvironment and its influence on response to therapy. It has been possible to identify different subclasses of immune environment that have an influence on tumor initiation and response and therapy; by parsing the unique classes and subclasses of tumor immune microenvironment (TIME) that exist within a patient's tumor, the ability to predict and guide immunotherapeutic responsiveness will improve, and new therapeutic targets will be revealed.Entities:
Mesh:
Year: 2018 PMID: 29686425 PMCID: PMC5998822 DOI: 10.1038/s41591-018-0014-x
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440